Effexor, Nasacort AQ, Vigamox Paragraph IV Certification Filed
This article was originally published in The Pink Sheet Daily
The first ANDA with a Paragraph IV certification for Wyeth's antidepressant Effexor (venlafaxine hydrochloride) was filed in November, according to FDA's list of updated filings
You may also be interested in...
The deal could give Wyeth more breathing room to launch its follow-on antidepressant.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.